 The independent Data Safety Monitoring Board DSMB has completed its prespecified data review for BioCardia Incs NASDAQ: BCDA ongoing Phase 3 CardiAMP Cell Therapy Heart Failure Trial. The DSMB based its review on all available data for the 108 patients enrolled with an additional six crossover patient procedures in the trial to date. 